{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:21:09Z","timestamp":1788967269736,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Opioid prescribing for a range of health issues is increasing globally. The risk of fatal and non-fatal overdose is increased among people prescribed strong opioids: in high doses in the context of polypharmacy (the use of multiple medications at the same time), especially with other sedatives; and among people with multiple morbidities including cardiorespiratory, hepatic and renal conditions. This study described and quantified the prescribing of strong opioids, comorbidities and other overdose risk factors among those prescribed strong opioids, and factors associated with high\/very high opioid dosage in a regional health authority in Scotland as part of a wider service improvement exercise.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Participating practices ran searches to identify patients prescribed strong opioids and their characteristics, polypharmacy, and other overdose risk factors. Data were anonymised before being analysed at practice and patient-level. Morphine Equivalent Doses were calculated for patients based on drug\/dose information and classed as Low\/Medium\/High\/Very High. Descriptive statistics were generated on the strong opioid patient population and overdose risk factors. The relationship between the prescribing of strong opioids and practice\/patient-level factors was investigated using linear and logistic regression models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eighty-five percent (46\/54) of GP practices participated. 12.4% (42,382\/341,240) of individuals in participating practices were prescribed opioids and, of these, one third (14,079\/42,382) were prescribed strong opioids. The most common comorbidities and overdose risk factors among strong opioid recipients were pain (67.2%), cardiovascular disease (43.2%), and mental health problems (39.3%). There was a positive significant relationship between level of social deprivation among practice caseload and level of strong opioid prescribing (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). People prescribed strong opioids tended to be older (mean 59.7\u2009years) and female (8638, 61.4%) and, among a subset of patients, age, gender and opioid drug class were significantly associated with prescribing of High\/Very High doses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings have identified a large population at potential risk of prescription opioid overdose. There is a need to explore pragmatic models of tailored interventions which may reduce the risk of overdose within this group and clinical practice may need to be tightened to minimise overdose risk for individuals prescribed high dose opioids.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-021-11162-4","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T23:05:41Z","timestamp":1624489541000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Quantifying prescribed high dose opioids in the community and risk of overdose"],"prefix":"10.1186","volume":"21","author":[{"given":"Joe","family":"Schofield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Steven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Matheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Baldacchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McAuley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Parkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,24]]},"reference":[{"key":"11162_CR1","unstructured":"National Records of Scotland. Drug-related deaths in Scotland in 2019. Edinburgh, 2020."},{"key":"11162_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/SAR.S144268","volume":"8","author":"LT Wu","year":"2017","unstructured":"Wu LT, Ghitza UE, Burns AL, Mannelli P. The opioid overdose epidemic: opportunities for pharmacists. Subst Abus Rehabil. 2017;8:53\u20135. https:\/\/doi.org\/10.2147\/SAR.S144268.","journal-title":"Subst Abus Rehabil"},{"key":"11162_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2147\/SAR.S108302","volume":"7","author":"JA Boscarino","year":"2016","unstructured":"Boscarino JA, Kirchner HL, Pitcavage JM, Nadipelli VR, Ronquest NA, Fitzpatrick MH, et al. Factors associated with opioid overdose: a 10-year retrospective study of patients in a large integrated health care system. Subst Abus Rehabil. 2016;7:131\u201341. https:\/\/doi.org\/10.2147\/SAR.S108302.","journal-title":"Subst Abus Rehabil"},{"key":"11162_CR4","unstructured":"World Health Organisation. World Health Organisation Model List for Essential Medicines, 21st List. 2019."},{"key":"11162_CR5","doi-asserted-by":"publisher","first-page":"l5823","DOI":"10.1136\/bmj.l5823","volume":"367","author":"BH Smith","year":"2019","unstructured":"Smith BH, Fletcher EH, Colvin LA. Opioid prescribing is rising in many countries. BMJ. 2019;367:l5823.","journal-title":"BMJ."},{"issue":"9","key":"11162_CR6","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jama.2018.0899","volume":"319","author":"EE Krebs","year":"2018","unstructured":"Krebs EE, Gravely A, Nugent S, Jensen AC, DeRonne B, Goldsmith ES, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. JAMA. 2018;319(9):872\u201382. https:\/\/doi.org\/10.1001\/jama.2018.0899.","journal-title":"JAMA."},{"issue":"5","key":"11162_CR7","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/ejp.1357","volume":"23","author":"J Bedson","year":"2019","unstructured":"Bedson J, Chen Y, Ashworth J, Hayward RA, Dunn KM, Jordan KP. Risk of adverse events in patients prescribed long-term opioids: a cohort study in the UK clinical practice research Datalink. Eur J Pain. 2019;23(5):908\u201322. https:\/\/doi.org\/10.1002\/ejp.1357.","journal-title":"Eur J Pain"},{"key":"11162_CR8","volume":"1","author":"M Noble","year":"2010","unstructured":"Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010;1:CD006605.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10180","key":"11162_CR9","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(19)30428-3","volume":"393","author":"MD Neuman","year":"2019","unstructured":"Neuman MD, Bateman BT, Wunsch H. Inappropriate opioid prescription after surgery. Lancet. 2019;393(10180):1547\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(19)30428-3.","journal-title":"Lancet"},{"issue":"2","key":"11162_CR10","first-page":"E119","volume":"17","author":"S Atluri","year":"2011","unstructured":"Atluri S, Sudarshan G, Manchikanti L. Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011. Pain Physician. 2011;17(2):E119\u201328.","journal-title":"Pain Physician"},{"issue":"10208","key":"11162_CR11","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","volume":"394","author":"L Degenhardt","year":"2019","unstructured":"Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet. 2019;394(10208):1560\u201379. https:\/\/doi.org\/10.1016\/S0140-6736(19)32229-9.","journal-title":"Lancet"},{"issue":"4","key":"11162_CR12","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/pm\/pny078","volume":"20","author":"B Larance","year":"2019","unstructured":"Larance B, Campbell G, Moore T, Nielsen S, Bruno R, Lintzeris N, et al. Concerns and help-seeking among patients using opioids for management of chronic noncancer pain. Pain Med. 2019;20(4):758\u201369. https:\/\/doi.org\/10.1093\/pm\/pny078.","journal-title":"Pain Med"},{"issue":"9859","key":"11162_CR13","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","volume":"380","author":"T Vos","year":"2012","unstructured":"Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990\u20132010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2163\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(12)61729-2.","journal-title":"Lancet"},{"issue":"5","key":"11162_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1037\/a0013628","volume":"16","author":"A Rosenblum","year":"2008","unstructured":"Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol. 2008;16(5):405\u201316. https:\/\/doi.org\/10.1037\/a0013628.","journal-title":"Exp Clin Psychopharmacol"},{"key":"11162_CR15","doi-asserted-by":"crossref","unstructured":"Meadowcroft D, Whitacre B. Do prescription drug monitoring programs encourage prescription \u2013 or illicit \u2013 opioid abuse?. Substance Abuse. 2021;42(1):65-75.","DOI":"10.1080\/08897077.2019.1695707"},{"key":"11162_CR16","doi-asserted-by":"crossref","unstructured":"Rhodes E, Wilson M, Robinson A, Hayden JA, Asbridge M. The effectiveness of prescription drug monitoring programs at reducing opioid-related harms and consequences: a systematic review. BMC Health Services Res. 2019;19 (1).","DOI":"10.1186\/s12913-019-4642-8"},{"key":"11162_CR17","doi-asserted-by":"crossref","unstructured":"M Mofizul Islam, Ian S McRae. An inevitable wave of prescription drug monitoring programs in the context of prescription opioids: pros, cons and tensions. BMC Pharmacology and Toxicology. 2014;15(1).","DOI":"10.1186\/2050-6511-15-46"},{"key":"11162_CR18","unstructured":"Scottish Government and NHS Scotland. Quality prescribing for chronic pain, a guide for improvement 2018\u20132021. 2018."},{"key":"11162_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.drugpo.2018.10.013","volume":"64","author":"TC Chen","year":"2019","unstructured":"Chen TC, Chen LC, Kerry M, Knaggs RD. Prescription opioids: regional variation and socioeconomic status - evidence from primary care in England. Int J Drug Policy. 2019;64:87\u201394. https:\/\/doi.org\/10.1016\/j.drugpo.2018.10.013.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"11162_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010276","volume":"6","author":"R Foy","year":"2016","unstructured":"Foy R, Leaman B, McCrorie C, Petty D, House A, Bennett M, et al. Prescribed opioids in primary care: cross-sectional and longitudinal analyses of influence of patient and practice characteristics. BMJ Open. 2016;6(5):e010276. https:\/\/doi.org\/10.1136\/bmjopen-2015-010276.","journal-title":"BMJ Open"},{"issue":"668","key":"11162_CR21","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.3399\/bjgp18X695057","volume":"68","author":"L Mordecai","year":"2018","unstructured":"Mordecai L, Reynolds C, Donaldson LJ, de C Williams AC. Patterns of regional variation of opioid prescribing in primary care in England: a retrospective observational study. Br J Gen Pract. 2018;68(668):e225\u2013e33. https:\/\/doi.org\/10.3399\/bjgp18X695057.","journal-title":"Br J Gen Pract"},{"issue":"1","key":"11162_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/ejp.520","volume":"19","author":"A Ruscitto","year":"2015","unstructured":"Ruscitto A, Smith BH, Guthrie B. Changes in opioid and other analgesic use 1995-2010: repeated cross-sectional analysis of dispensed prescribing for a large geographical population in Scotland. Eur J Pain. 2015;19(1):59\u201366. https:\/\/doi.org\/10.1002\/ejp.520.","journal-title":"Eur J Pain"},{"issue":"6","key":"11162_CR23","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.bja.2018.02.022","volume":"120","author":"N Torrance","year":"2018","unstructured":"Torrance N, Mansoor R, Wang H, Gilbert S, Macfarlane GJ, Serpell M, et al. Association of opioid prescribing practices with chronic pain and benzodiazepine co-prescription: a primary care data linkage study. Br J Anaesth. 2018;120(6):1345\u201355. https:\/\/doi.org\/10.1016\/j.bja.2018.02.022.","journal-title":"Br J Anaesth"},{"issue":"6","key":"11162_CR24","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/j.drugpo.2013.05.007","volume":"24","author":"H Keane","year":"2013","unstructured":"Keane H. Categorising methadone: addiction and analgesia. Int J Drug Policy. 2013;24(6):e18\u201324. https:\/\/doi.org\/10.1016\/j.drugpo.2013.05.007.","journal-title":"Int J Drug Policy."},{"key":"11162_CR25","unstructured":"Scottish Drugs Forum. Older people with Drug Problems in Scotland: Addressing the needs of an ageing population. The Expert Working Group on Older People with a Drug Problem, Final Report. June 2017."},{"issue":"2","key":"11162_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/01.j.pain.0000460303.63948.8e","volume":"156","author":"G Campbell","year":"2015","unstructured":"Campbell G, Nielsen S, Bruno R, Lintzeris N, Cohen M, Hall W, et al. The pain and opioids IN treatment study: characteristics of a cohort using opioids to manage chronic non-cancer pain. Pain. 2015;156(2):231\u201342. https:\/\/doi.org\/10.1097\/01.j.pain.0000460303.63948.8e.","journal-title":"Pain."},{"issue":"12","key":"11162_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080095","volume":"8","author":"KD Rogers","year":"2013","unstructured":"Rogers KD, Kemp A, McLachlan AJ, Blyth F. Adverse selection? A multi-dimensional profile of people dispensed opioid analgesics for persistent non-cancer pain. PLoS One. 2013;8(12):e80095. https:\/\/doi.org\/10.1371\/journal.pone.0080095.","journal-title":"PLoS One"},{"issue":"1","key":"11162_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12885-019-6472-9","volume":"20","author":"H Fowler","year":"2020","unstructured":"Fowler H, Belot A, Ellis L, Maringe C, Luque-Fernandez MA, Njagi EN, et al. Comorbidity prevalence among cancer patients: a population-based cohort study of four cancers. BMC Cancer. 2020;20(1):2. https:\/\/doi.org\/10.1186\/s12885-019-6472-9.","journal-title":"BMC Cancer"},{"issue":"2","key":"11162_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1192\/bjp.2017.25","volume":"212","author":"JF Scherrer","year":"2018","unstructured":"Scherrer JF, Salas J, Sullivan MD, Ahmedani BK, Copeland LA, Bucholz KK, et al. Impact of adherence to antidepressants on long-term prescription opioid use cessation. Br J Psychiatry. 2018;212(2):103\u201311. https:\/\/doi.org\/10.1192\/bjp.2017.25.","journal-title":"Br J Psychiatry"},{"issue":"3","key":"11162_CR30","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/acer.13594","volume":"42","author":"K Witkiewitz","year":"2018","unstructured":"Witkiewitz K, Vowles KE. Alcohol and opioid use, co-use, and chronic pain in the context of the opioid epidemic: a critical review. Alcohol Clin Exp Res. 2018;42(3):478\u201388. https:\/\/doi.org\/10.1111\/acer.13594.","journal-title":"Alcohol Clin Exp Res"},{"key":"11162_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.copsyc.2018.12.020","volume":"30","author":"KJ Langdon","year":"2019","unstructured":"Langdon KJ, Dove K, Ramsey S. Comorbidity of opioid-related and anxiety-related symptoms and disorders. Curr Opin Psychol. 2019;30:17\u201323. https:\/\/doi.org\/10.1016\/j.copsyc.2018.12.020.","journal-title":"Curr Opin Psychol"},{"key":"11162_CR32","unstructured":"Faculty of Pain Medicine of the Royal College of Anaesthetists. Opioids Aware 2021 https:\/\/www.fpm.ac.uk\/opioids-aware. Accessed 4 February 2021."},{"key":"11162_CR33","doi-asserted-by":"crossref","unstructured":"Dowell D, Haegerich TM, Chou R. Center for Disease Control and Prevention Guidelines for prescribing opioids for chronic pain \u2014 United States, 2016. 2016.","DOI":"10.1001\/jama.2016.1464"},{"key":"11162_CR34","doi-asserted-by":"crossref","unstructured":"Alvarez-Madrazo S, McTaggart S, Nangle C, Nicholson E, Bennie M. Data Resource Profile: The Scottish National Prescribing Information System (PIS). Int J Epidemiol. 2016;45 (3):714-5.","DOI":"10.1093\/ije\/dyw060"},{"key":"11162_CR35","unstructured":"National Institute for Health and Care Excellence. British National Formulary: BMJ Group & Pharmaceutical Press; 2021. https:\/\/bnf.nice.org.uk\/. Accessed 4 February 2021."},{"key":"11162_CR36","unstructured":"EMIS Web. EMIS health Leeds, England 2021 https:\/\/www.emishealth.com\/products\/emis-web. Accessed 4 February 2021."},{"issue":"3","key":"11162_CR37","doi-asserted-by":"publisher","first-page":"173","DOI":"10.14236\/jhi.v19i3.811","volume":"19","author":"T Benson","year":"2011","unstructured":"Benson T. The history of the read codes: the inaugural James read memorial lecture 2011. Inform Prim Care. 2011;19(3):173\u201382. https:\/\/doi.org\/10.14236\/jhi.v19i3.811.","journal-title":"Inform Prim Care"},{"key":"11162_CR38","unstructured":"Public Health Scotland. The Scottish Index of Multiple Deprivation (SIMD) Edinburgh, Scotland 2021. https:\/\/www.isdscotland.org\/Products-and-Services\/GPD-Support\/Deprivation\/SIMD\/. Accessed 4 February 2021."},{"key":"11162_CR39","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.r-project.org\/. Accessed 4 February 2021."},{"key":"11162_CR40","unstructured":"Faculty of Pain Medicine of the Royal College of Anaesthetists. A structured approach to opioid prescribing, dose equivalents and changing opioids 2021. https:\/\/fpm.ac.uk\/opioids-aware-structured-approach-opioid-prescribing\/dose-equivalents-and-changing-opioids. Accessed 4 February 2021."},{"key":"11162_CR41","unstructured":"Centers for Disease Control and Prevention. Calculating Total Daily Dose of Opioids For Safer Dosage, Factsheet. 2018."},{"key":"11162_CR42","unstructured":"Public Health Scotland. GP Clusters, General Practice 2021. https:\/\/www.isdscotland.org\/Health-Topics\/General-Practice\/GP-Clusters\/. Accessed 4 February 2021."},{"key":"11162_CR43","unstructured":"Scottish Intercollegiate Guidelines Network. SIGN 136, Management of Chronic Pain: A national clinical guideline. Edinburgh; 2019."},{"key":"11162_CR44","doi-asserted-by":"publisher","first-page":"100592","DOI":"10.1016\/j.eclinm.2020.100592","volume":"28","author":"G Campbell","year":"2020","unstructured":"Campbell G, Noghrehchi F, Nielsen S, Clare P, Bruno R, Lintzeris N, et al. Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: findings from a 5-year prospective cohort study. EClinicalMedicine. 2020;28:100592. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100592.","journal-title":"EClinicalMedicine."},{"key":"11162_CR45","doi-asserted-by":"crossref","unstructured":"Campion EW, Babu KM, Brent J, Juurlink DN. Prevention of Opioid Overdose. New England J Med. 2019;380(23):2246-55.","DOI":"10.1056\/NEJMra1807054"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-021-11162-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-021-11162-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-021-11162-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T23:22:35Z","timestamp":1624490555000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-021-11162-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,24]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["11162"],"URL":"https:\/\/doi.org\/10.1186\/s12889-021-11162-4","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,24]]},"assertion":[{"value":"9 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NHS Fife\u2019s Research and Development Office waived the need to secure either NHS ethical approval or informed patient consent for this project which was conducted as part of a service improvement process. The data were routinely collected in the delivery of primary healthcare and fully anonymised\u00a0to remove patient identifiers before being analysed. All methods were conducted in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1174"}}